INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative disease affecting the central nervous system [1] [2] [3] . More than 2 million people worldwide are affected by this disease, with more than two-thirds of these patients suffering from the relapsing-remitting MS (RRMS) form of the disease [4, 5] . Patients with relapsing forms of MS experience sporadic relapses that are typically associated with neurologic impairment, disability, and a decrease in overall health and quality of life [5, 6] . There is extensive variability in the frequency, duration, and severity of symptoms, as well as the extent of recovery [5] . MS begins with the formation of acute inflammatory lesions. Such lesions are often clinically 'silent' and have been estimated to be about 10 times more frequent than episodes of clinical worsening [7, 8] . This subclinical tissue damage can be visualized by magnetic resonance imaging (MRI). Early in the disease process, the inflammatory activity eventually becomes clinically manifested as a clinically isolated syndrome (CIS)-the first episode of clinically apparent neurologic episodes.
The degenerative processes associated with the progression of the disease include axonal loss in lesions, diffuse damage to white matter distant from areas shown to be involved by histopathology or MRI, and atrophy of deep and cortical grey matter. The later stages of relapsing MS are associated with the accumulation of neuronal loss and gliosis [7] . Therefore, initiating treatment early in the course of relapsing MS could potentially slow disease progression. In fact, clinical trials with interferon b and glatiramer acetate (GA) have shown that early treatment was associated with improved outcomes, including a prolonged time to conversion from CIS to clinically definite MS (CDMS) and a reduction in the number and volume of lesions detected by MRI [9] [10] [11] [12] [13] [14] [15] [16] .
Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) is a novel, oral MS therapeutic approved for the treatment of patients with relapsing forms of MS. Treatment with DMF has been shown in 2 pivotal Phase 3 trials (DEFINE and CONFIRM) to result in significant reductions in clinical and MRI activity and have a favorable benefit-risk profile in patients with RRMS [17, 18] . 
Efficacy Assessments
The primary efficacy endpoints were the proportion of patients relapsed at 2 years in DEFINE and ARR at 2 years in CONFIRM. Analyses were performed using SAS version 9.3 software (SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible 
RESULTS

Study Population
The DEFINE and CONFIRM study populations included 444 patients treated with PBO or DMF 240 mg BID who met the criteria for newly diagnosed, of whom 362 completed the parent study (189 PBO and 173 DMF) [19] . Specifically, the median EDSS at the end of 6 years remained 2.0, the same as the median EDSS at baseline.
AEs
In the newly diagnosed population, overall incidence of AEs was similar between PBO/ DMF-treated (94%) and DMF/DMF-treated patients (92%; Access of the central nervous system by autoreactive lymphocytes is thought to trigger a cascade of events that initiate the demyelination, axonal transection, and neurodegeneration associated with RRMS. This is followed by extensive neuronal loss and gliosis in later stages [7, 26] . Therefore, therapeutic interventions in newly diagnosed patients with RRMS may have the greatest potential to slow the accumulation of damage in the long term. This assertion is supported by findings that long-term outcomes are poorer in patients with a greater frequency of relapse and higher lesion load in early MS [27] [28] [29] . This evidence supports the notion that the opportunity for maximal therapeutic effect has an early window, with the association between MS disease activity and long-term clinical prognosis becoming attenuated over time. [28, Based on this post hoc analysis, DMF demonstrated a safety and tolerability profile in newly diagnosed patients that was comparable with that of the ENDORSE overall safety population [37] . Flushing, nasopharyngitis, and MS relapse were among the most common AEs reported by both DMF/ DMF and PBO/DMF newly diagnosed patients.
In the overall ENDORSE safety population, the Upper respiratory tract infection 29 (20) 11 (13) Urinary tract infection 24 (17) 9 (11) Headache 20 (14) 14 (16) Diarrhea 20 (14) 11 (13) Back pain 19 (13) 9 (11) Fatigue 13 (9) 10 (12) Upper abdominal pain 5 (3) 9 (11) Pain in extremity 15 (10) 7 (8) AE adverse event, MS multiple sclerosis, PBO placebo a DMF delayed-release dimethyl fumarate (also known as gastro-resistant DMF) most common AEs were MS relapse and nasopharyngitis in the DMF/DMF patients, while flushing and gastrointestinal (GI)-related events were more common among patients previously treated with PBO and new to DMF treatment [37] . This is not surprising given the well-known observation that flushing and GI-related events tended to be transient and decrease substantially after the first 1-2 months.
The incidence of AEs leading to discontinuation were higher in newly diagnosed patients with RRMS who were new to DMF in ENDORSE (PBO/DMF; 18%) compared with those receiving continuous treatment (DMF/DMF; 9%). This is consistent with the overall population, in which 17% of PBO/DMF and 7% DMF/DMF patients discontinued due to
AEs. The observation that a higher proportion of patients new to DMF discontinued due to AEs, in both the newly diagnosed and overall population, can largely be explained by the occurrence of flushing and GI events that tend to occur early in therapy with DMF [17, 18, 38] .
Rates of discontinuation due to individual GI-related AEs were similar in patients new to DMF in the newly diagnosed cohort compared with the overall population (B3% discontinued due to individual GI-related AEs). Among patients new to DMF, 4% and 0% discontinued due to flushing in the overall population and newly diagnosed cohort, respectively. In patients continuing DMF, B1% of patients each discontinued due to flushing or GI-related events in both the overall population and the newly diagnosed cohort. Compliance with Ethics Guidelines. All 
CONCLUSIONS
